Minimum infective dose of severe acute respiratory syndrome coronavirus 2 based on the current evidence: A systematic review

SeyedAhmad SeyedAlinaghi1, Amirali Karimi2, Hengameh Mojdeganlou3, Zahra Pashaei1, Pegah Mirzapour1, Ahmadreza Shamsabadi4, Alireza Barzegary5, Fatemeh Afroughi5,6, Soheil Dehghani2, Nazanin Janfaza7, Amirata Fakhfouri5, Sepideh Khodaei1, Esmaeil Mehraeen8, and Omid Dadras9

Abstract

Objective: Understanding the minimum infective dose is significant for risk assessment in the performance of suitable infection control strategies in healthcare centers. However, the literature lacks strong evidence regarding this value for severe acute respiratory syndrome coronavirus 2. Therefore, the aim of this study was to investigate the minimum infectious dose of coronavirus disease 2019.

Methods: We searched the databases of PubMed, Scopus, Web of Science, and Cochrane and retrieved all the relevant literature by 25 July 2021. The records were downloaded into the EndNote software and underwent title/abstract and full-text screenings. A summary of included studies was organized into tables for further analysis, interpretation, and drafting of the results.

Results: Nineteen studies including the laboratory data on human and animal hosts were selected based on the eligibility criteria. All the literature reported on the infective dose, particularly in humans. The main methods for measurement of infection were through tissue culture infectious dose (TCID50) and counting plaque-forming units. The range of minimum infective was 1.26–7 × 10^6.25 PFU.

Conclusion: In this study, we have presented a range of minimum infective doses in humans and various animal species. Such numbers can possibly vary between the individuals based on numerous demographic, immunologic, or other factors.

Keywords
Coronavirus disease 2019, minimum infective dose, severe acute respiratory syndrome coronavirus 2

Introduction

The World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) disease as a global public health emergency on 30 January 2020.1,2 COVID-19 started its devastating trajectory into a global pandemic in Wuhan, China.3–5 COVID-19 spread rapidly around the world. Globally, as of 28 March 2022, more than 480 million
confirmed cases and 6.1 million deaths due to COVID-19 were reported to the WHO. Most patients with COVID-19 are asymptomatic or show mild symptoms such as fever, upper respiratory tract symptoms, shortness of breath, and diarrhea, but the more severe cases can lead to pneumonia, multiple organ failure, and death. The newly emerged virus that caused the COVID-19 was named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses (ICTV) on 11 February 2020. Coronaviruses are a large family of single-stranded RNA viruses that infect animals and humans and cause respiratory, gastrointestinal, liver, and neurological diseases.

Coronaviruses are further divided into four genera: alpha-coronavirus, beta-coronavirus, gamma-coronavirus, and delta-coronavirus.

There were six most identified coronaviruses before 2019 that affected the humans: (1) human coronavirus 229E (HCoV-229E), (2) human coronavirus OC43 (HCoV-OC43), (3) severe acute respiratory syndrome coronavirus (SARS-CoV), (4) human coronavirus NL63 (HCoV-NL63), (5) human coronavirus HKU1 (HCoV-HKU1), and (6) Middle East respiratory syndrome coronavirus (MERS-CoV).

The first four are recognized as endemic (that is, these are associated with mild and self-limiting diseases), the last two cases lead to severe illness and death. The seventh strain of the corona virus is SARS-CoV-2, also called COVID-19. This strain causes severe disease and respiratory infections in humans and is widespread.

The SARS-CoV-2 genome has great sequence similarity (89%–96.3%) with two bat coronaviruses, bat-SLCoVZC45 and bat-SL-CoVZXC21, and 79%–82% with that of human SARS-CoV. The genome consists of 14 kilo bases that encode 27 proteins. The 5′ terminus encoding for 15 non-structural proteins collectively involved in virus replication and possibly in immune evasion. The 3′ terminus of the genome encodes for structural and accessory proteins.

Dose means the number of particles to cause a detectable infection. For understanding viral pathogenicity, determining the number of particles that trigger infection is crucial. Low infectious doses mean that the organism is highly contagious from person to person through contact with infected surfaces. In a US study, isolation of SARS-CoV-2 from a sample of the oropharynx and nasopharynx, one patient and inoculation into Vero cells showed that SARS-CoV-2 proliferated rapidly, reaching 10^6 TCID_50/mL within 24h.

SARS-CoV-2 infection requires a minimal dose of infection because lower doses can be safe. The minimum infectious dose indicates how much virus has entered the body and caused the infection. To determine the pattern of transmission, we need the minimum infectious dose of the virus. Given the importance and necessity of the topic, we aimed to review the literature on the minimum infectious dose of SARS-CoV-2 to identify what was the lowest range of SARS-CoV-2 dose that caused the COVID-19 in the related studies.

**Methods**

This review study was designed to encompass all the evidence related to the infective dose of COVID-19 that has been published by 25 July 2021. The authors aimed to investigate the minimum infective dose of novel coronavirus (SARS-CoV-2) and to ensure the reliability and validity of the results, the preferred reporting items for systematic reviews and meta-analyses (PRISMA) checklist was applied (Supplemental Material 1).

**Data sources**

The relevant literature was retrieved by a systematic search of the keywords on the online databases comprising PubMed, Web of Science, Scopus, and Cochrane, we extracted all pertinent records published from December 2019 to 25 July 2021. The search strategy contemplated numerous keyword combinations that were identified through the MeSH (medical subject headings) database or previous articles. All the search strategies were recorded in the Supplemental Material 2, but the final search for PubMed is presented below in the query [C] (all the keywords were searched as title/abstract):

A. “COVID-19” OR “SARS-CoV-2” OR “SARS-CoV2” OR “2019-nCoV” OR “Novel Coronavirus.”

B. “Infective dose” OR “Infectious dose” OR “Minimum infective dose” OR “Minimum infectious dose” OR “Minimal infective dose” OR “minimum viral load” OR “minimum infectious viral load” OR “minimum infective level” OR “minimum infectious level” OR “Tissue culture infectious dose” OR “Plaque forming unit.”

C. [A] AND [B].

**Study selection**

Three independent researchers screened the retrieved studies and selected that serve the objectives of the present review by titles and abstracts. Later, the full texts of these articles were inspected carefully and based on the eligibility criteria, the most relevant studies were included in the qualitative synthesis. We included the original studies (including laboratory, animal, and human studied) that assessed the COVID-19 minimum infective dose. We also included the pre-prints as the number of studies on this matter is limited.

As part of the eligibility protocol, we deemed the exclusion criteria as below:

- Non-original studies, including review articles and meta-analyses.
- Publications with inaccessible full texts, conference abstracts, and abstract articles.
- Ongoing clinical trials that lack published results.
Data extraction
A summary of findings and minimum infective dose of COVID-19 were prepared and included in two tables by five researchers. The first table describes the characteristics of the studies and participants including first author information, type of study (e.g. experimental), publication year, country of origin, study population, age and gender, signs and symptoms, comorbidities, and laboratory data. The second table addresses host type, sampling site and method, mode of transmission, minimum infective dose, symptomatic cases (%), and clinical outcomes (%). Ultimately, other co-authors double-checked each of the selected publications to avoid potential duplications or overlaps, if any exist in the results.

Quality/risk of bias assessment
We used the Newcastle–Ottawa scale (NOS) to assess the quality of the included studies. A maximum score of 9 will be allocated to the studies based on three categories of selection, comparability, and exposure/outcome.

Statistical analysis
As this study is a systematic review and not a meta-analysis, we did not aim to conduct any statistical analysis.

Results
Following a systematic search on online databases, 439 total records were identified. After duplicate removal and title/abstract screening, 298 and 77 of them remained, respectively. Finally, 19 eligible studies including human and animal subjects were included to assess the minimum infective dose, route of transmission, signs and symptoms, and outcomes of COVID-19 infection (Figure 1). Studies were conducted in six countries. Most of the studies were from the United States (n = 8), followed by China (n = 6) and Canada (n = 2). The majority of studies were experimental (n = 13), and some of them were human studies (n = 6). Experimental studies were conducted on golden Syrian hamsters (n = 5), mice (n = 3), African green monkeys (n = 3), Rhesus macaques (n = 1), and ferrets (n = 1) (Table 1).

The main methods for reporting the infective dose were through tissue culture infectious dose (TCID₅₀) and by counting plaque-forming units (PFU).

In TCID₅₀, the viral dose in 5% of inoculated tissue culture made pathological changes or cell death. PFU is estimated of viral concentration in plaque-forming units by measuring the number of particles that form a plaque. The minimum infective doses have been summarized in Table 2.

Human studies on infective dose of SARS-CoV-2
We found no experimental studies that assess the infective dose in human, so we included observational human studies. The minimum infective dose of SARS-CoV-2 causing COVID-19 in humans in assessed cross-sectional and case-series studies was low; in a case-series study that investigated infective dose in 273 specimens from 15 SARS-CoV-2-positive patients, detected minimum infective dose was 1.26 PFU in vitro in the COVID-19-RdRp/He assay. In another study, 248 oro-nasopharyngeal samples of COVID-19 individuals were assessed, and infective dose was reported to be 364 PFU. In a case-series study which assessed 97 children 10 years and lower, 78 children aged 11–17 years, and 130 adults, the infective dose in 11–17 years children was lower than two other groups (125 PFU). Children had lower live virus growth, higher cycle thresholds, and lower viral concentration in comparison with adults, so children are not the main carriers of infection. Children aged ≤10 years were more likely to be asymptomatic than others.

Animal studies
Tables 1 and 2 summarize experimental studies of different animals on SARS-CoV-2.

Ferret. Intranasal inoculation of SARS-CoV-2 virus in three level of low (500 PFU), medium (50,000 PFU), and high (5,000,000 PFU) caused symptoms in 72% of ferrets. In all ferrets of medium and high group (n = 66%), that were infected at a dose of 50 000 PFU, and 5,000,000 PFU, respectively, mild multifocal bronchopneumonia was observed. Also, in medium and high groups and one ferret of low group, viral RNA shedding in the upper respiratory tract was observed. At the end of study, all of the ferrets were alive.

Mice. A study on 23 transgenic mice after aerosol inoculation at a dose of 630 PFU of SARS-CoV-2 showed weight loss and 43.5% (n = 10) of them were infected based on serological analyses. Another study on 34 transgenic mice after infection at a dose of 70,000 PFU by intranasal route showed weight loss, interstitial pneumonia, and virus replication in the lungs. In K18-hACE2 mice infected by the intraperitoneal injection at a dose of 10,000 PFU of SARS-CoV-2, 75% body weight loss, lethargy, ruffled fur, hunched posture, and labored breathing. Also, at the end of study, the mice died. In Ad-hACE2 Mice, infected with same route and dose, viral titers at the day 2 post-infection were seen in the lungs.

African green monkey. All six African green monkeys exposed to 280,000 PFU by the intranasal route had pulmonary consolidation with hyperemia and hemorrhage. Three of them had multifocal neutrophilicbroncho-interstitial pneumonia.
Also, declined appetite, increased temperature, hypercapnia, gas distinction of small intestines showed in three of them. African green monkeys inoculated by combined intrathecal and intranasal routes at a dose of $5.0 \times 10^5$ PFU showed decreased appetite, fever, hyperemia multifocal lesions of each lobe, mild lymphoid enlargement, pulmonary edema and pulmonary hemorrhage, pneumonia, and the small intestine was somewhat loose and dilated with gas and yellow fluid. At a dose of 38,400 PFU, they showed fever, lung opacity, and mild hypoxia. Exposure to higher dose leads to moderate pulmonary symptoms in a group of rhesus macaques infected at a dose of 700,000 PFU by combined intranasal, intrathecal, and conjunctivally routes.

**Cynomolgus macaques.** All cynomolgus macaques infected with SARS-CoV-2 at a dose of 38,400 PFU via airborne presented fever, mild hypoxia, rectal bleeding, and lung opacity.

**Hamsters.** In two groups of hamsters infected with SARS-CoV-2 by intranasal routes at a dose of 700 PFU and 70,000 PFU, respectively, weight loss was shown. Also, higher dose–infected hamsters presented lung injury, and morbidity,

---

**Figure 1.** PRISMA flow diagram of the study selection process.

---

**Also, declined appetite, increased temperature, hypercapnia, gas distinction of small intestines showed in three of them.** African green monkeys inoculated by combined intrathecal and intranasal routes at a dose of $5.0 \times 10^5$ PFU showed decreased appetite, fever, hyperemia multifocal lesions of each lobe, mild lymphoid enlargement, pulmonary edema and pulmonary hemorrhage, pneumonia, and the small intestine was somewhat loose and dilated with gas and yellow fluid. At a dose of 38,400 PFU, they showed fever, lung opacity, and mild hypoxia. Exposure to higher dose leads to moderate pulmonary symptoms in a group of rhesus macaques infected at a dose of 700,000 PFU by combined intranasal, intrathecal, and conjunctivally routes.

**Cynomolgus macaques.** All cynomolgus macaques infected with SARS-CoV-2 at a dose of 38,400 PFU via airborne presented fever, mild hypoxia, rectal bleeding, and lung opacity.

**Hamsters.** In two groups of hamsters infected with SARS-CoV-2 by intranasal routes at a dose of 700 PFU and 70,000 PFU, respectively, weight loss was shown. Also, higher dose–infected hamsters presented lung injury, and morbidity,
| ID | First author (reference) | Type of study | Publication year | Country | Study population | Age | Gender (%) | Sign and symptoms | Laboratory data |
|----|--------------------------|---------------|------------------|---------|------------------|-----|------------|-------------------|-----------------|
| 1  | Bao et al.14             | Experimental (animal study) | 2020 | China | 34 transgenic mice | 6–11 months old | Male/female | Weight loss, interstitial pneumonia, and virus replication in the lungs | N/A |
| 2  | Bao et al.15             | Experimental (animal study) | 2020 | China | 23 transgenic mice | 4–6 months old | Male/female | Weight loss | Based on serological analyses, 10 out of 23 mice were infected after direct contact and respiratory droplets exposure |
| 3  | Basu16                   | Cross-sectional | 2021 | USA | 2 SARS-CoV-2-positive samples | 49 (37 and 61 years old) | Female (100) | N/A | N/A |
| 4  | Bullard et al.17         | Cross-sectional | 2021 | Canada | 90 SARS-CoV-2-positive samples | 45 | Male (49) Female (51) | N/A | N/A |
| 5  | Bullard et al.18         | Case series | 2021 | Canada | 305 COVID-19 patients (97 children aged ≤10 years, 78 children aged 11–17 years, 130 adults) | N/A | N/A | N/A | N/A |
| 6  | Chan et al.19            | Case series | 2020 | China | 273 Specimens from SARS-CoV-2-positive patients | N/A | N/A | N/A | N/A |
| 7  | Cross et al.20           | Experimental (animal study) | 2020 | USA | 6 African green monkeys | N/A | N/A | Declined appetite, increased temperature, hypercapnia (3/6), gas distillation of small intestines. All monkeys had pulmonary consolidation with hyperemia and hemorrhage. Three of them had multifocal neutrophilic broncho-interstitial pneumonia | N/A |
| 8  | Deng et al.21            | Experimental (animal study) | 2020 | China | 5 Rhesus macaques | 3-5 years old | Male (100) | Opaque glass signs, obscure lung marking, severe progressive pulmonary infiltration, patchy lesions, increased density, and interstitial pneumonia appeared in the lungs | N/A |
| 9  | Dhakal et al.22          | Experimental (animal study) | 2021 | USA | Golden Syrian hamsters | 8–10 week | Male/female | Bodyweight loss, lung injury | N/A |
| 10 | Johnston et al.23        | Experimental (animal study) | 2021 | USA | 3 naïve African green monkeys | N/A | N/A | Fever, lung opacity, mild hypoxia and erythema around the eyes, rectal bleeding | N/A |
| 11 | Kumar et al.24           | Experimental (animal study) | 2021 | USA | Male Syrian golden hamsters | N/A | N/A | N/A | N/A |

(Continued)
| ID | First author (reference) | Type of study | Publication year | Country | Study population | Age | Gender (%) | Sign and symptoms | Laboratory data |
|----|--------------------------|---------------|------------------|---------|------------------|-----|------------|------------------|----------------|
| 12 | Rathnasinghe et al. | Experimental (animal study) | 2020 | USA | 2 hACE2 mice | 6 weeks old | Female (100) | In K18-hACE2 mice: 75% body weight loss, lethargy, ruffled fur, hunched posture, and labored breathing | Rathnasinghe et al. |
| 13 | Rosenke et al. | Experimental (animal study) | 2020 | USA | 24 Syrian hamsters | 4–6 weeks old and >27 weeks old | Male/female | Moderate broncho-interstitial pneumonia, along with high viral load in lungs and extensive virus shedding. Minor changes in respiratory pattern, lung lesions, loss of <10% body weight | In oral and rectal swabs high levels of viral gRNA were detected. On day 11 after infection, all oral swabs were positive and suggested that viral replication in upper respiratory areas was still ongoing |
| 14 | Ryan et al. | Experimental (animal study) | 2021 | UK | 18 ferrets (three groups, every 6 ferrets) | N/A | Male/Female | Pneumocyte hyperplasia and weight loss | In all ferrets of medium and high group: mild multifocal bronchopneumonia |
| 15 | Sia et al. | Experimental (animal study) | 2020 | China | Golden hamsters | 4–5 weeks | Male (100) | Rhinitis, cough, elevated temperature, shortness of breath, or sudden loss of sense of taste or smell | N/A |
| 16 | Song et al. | Experimental (animal study) | 2021 | China | 18 hamsters | 12 weeks | Male/female | N/A | N/A |
| 17 | Van der Moeren et al. | Cross-sectional | 2021 | Netherlands | 248 (74 qRT-PCR positives, 174 qRT-PCR negatives) clinical combined oro-nasopharyngeal samples of individuals with COVID-19-like symptoms | N/A | N/A | Rhinitis, cough, elevated temperature, shortness of breath, or sudden loss of sense of taste or smell | DAA result: positive = 54 (Ct-value 12.2–27.7), negative = 20 (Ct-value 22.6–39.5) |
| 18 | Woolsey et al. | Experimental (animal study) | 2020 | USA | 6 adult African green monkeys | N/A | N/A | Decreased appetite, fever, and hyperemia in multifocal lesions of each lobe. The small intestine was somewhat loose and dilated with gas and yellow fluid. Mild lymphoid enlargement. Pulmonary edema and pulmonary hemorrhage. Pneumonia. | N/A |
| 19 | Yamayoshi et al. | Case series | 2020 | Japan | SARS-CoV-2-positive samples | N/A | N/A | N/A | N/A |

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; COVID-19: coronavirus disease 2019; qRT-PCR: quantitative real-time polymerase chain reaction; ALT: alanine aminotransferase; CRP: C-reactive protein; aPTT: activated partial thromboplastin time; CJ: conjunctivally; IT: intratracheally.
Table 2. Minimum infective dose of the subjects and related details of the studies.

| ID | First author (reference) | Host | Sampling site and method | Mode of transmission | Minimum infective dose | Symptomatic cases (%) | Clinical outcome (%) |
|----|--------------------------|------|--------------------------|----------------------|------------------------|----------------------|----------------------|
| 1  | Bao et al.14             | tgMice | RT-qPCR, heart, liver, spleen, lung, kidney, brain, intestine, and testis | IN | 70,000 PFU | 3 | All were alive at the end of the study |
| 2  | Bao et al.15             | hACE2 mice | Throat and anal swab | Aerosol | 630 PFU | 39 | All were alive at the end of the study |
| 3  | Basu16                   | Human | Nasopharyngeal swab, computed tomography | Droplet | 330 PFU | 100 | Both of them were alive |
| 4  | Bullard et al.17         | Human | RT-PCR Nasopharyngeal (NP) or endotracheal (ETT) | Tissue culture | 197 PFU | 28.9 | N/A |
| 5  | Bullard et al.18         | Human | RT-PCR Nasopharyngeal swabs | N/A | Children aged ≤10 years = 221 PFU | 75.4 | All were alive at the end of the study. Children had lower live virus growth, higher cycle thresholds, and lower viral concentration in comparison with adults, so children are not the main carriers of infection. Children aged ≤10 years were more likely to be asymptomatic than others. |
| 6  | Chan et al.19            | Human | RT-qPCR Nasopharyngeal aspirate/swabs, throat swab, a sputum specimen | N/A | 1.26 PFU in vitro in the COVID-19-RdRp/Hel assay | N/A | N/A |
| 7  | Cross et al.20           | African green monkey | Blood and mucosal swabs | IN | 2,800,000 PFU | 100 | All alive |
| 8  | Deng et al.21            | Rhesus macaques | Nasal, throat, conjunctival, and anal swabs | CJ, IT, IG | 700,000 PFU | 100 | All alive. All of them are infected via CJ and IT routes but not the IG route. |
| 9  | Dhakal et al.22          | Golden Syrian hamsters | Blood, nasal turbinate, trachea, and lung samples, Antibody and cytokine ELISA, computed tomography (CT), and qPCR | IN | 70,000 PFU | 100 | All were alive at the end of the study. Male experienced greater morbidity, greater body mass loss, more extensive pneumonia, and recovery slower than females |
| 10 | Johnston et al.23        | Monkey Rhesus Macaques | Oropharyngeal (OP) and nasopharyngeal (NP), and rectal swabs | Airborne | 38,400 PFU | 100 | N/A |
| 11 | Kumar et al.24           | Syrian golden hamsters | N/A | IN | 10,000,000 PFU | 100 | N/A |
| 12 | Rathnasinghe et al.25    | Mice | qRT-PCR: Lung samples | Injection | 10,000 PFU | 50 | In K18-hACE2 mice: dead |
| 13 | Rosenke et al.26         | Hamsters | qRT-PCR: Blood samples and oral and rectal swabs | IN | 700 PFU | 100 | All were alive at the end of the study |
| 14 | Ryan et al.27            | Ferrets | RT-qPCR: Nasal washes, throat, and rectal swabs | IN | Low: 500 PFU Medium: 50,000 PFU High: 5,000,000 PFU | 72 | All were alive at the end of the study |
| 15 | Sia et al.28             | Hamster | RT-PCR: Nasopharyngeal aspirate and throat swab | Aerosols | 7 × 10^12 PFU | 50 | N/A |

(Continued)
| ID | First author (reference) | Host | Sampling site and method | Mode of transmission | Minimum infective dose | Symptomatic cases (%) | Clinical outcome (%) |
|----|--------------------------|------|--------------------------|----------------------|------------------------|----------------------|----------------------|
| 16 | Song et al.29            | Hamster | qRT-PCR: Throat swabs | IN | 700,000 PFU | SARS-CoV-2-infected but not mock-infected animals exhibited progressively body weight loss from 1 to 9 dpi. The infected animals exhibited severe weight loss at 5 days dpi (8.91%), which peaked at 9 dpi (18.02%), then gradually regained their weight by 14 dpi (5.04%) | Alveolar damage, involvement of the spleen, lymph nodes, different segments of the alimentary tract, kidney, adrenal gland, ovary, vesicular gland and prostate damage, gallbladder, myocardium, and lymph nodes. All the infected hamsters displayed severe systemic inflammatory responses |
| 17 | Van der Moeren et al.30  | Human | qRT-PCR: Combined oropharyngeal and nasopharyngeal flocked swab | N/A | 364 PFU | 29.9 | N/A |
| 18 | Woolsey et al.31         | Monkey | RT-qPCR mucosal swabs: BAL whole blood or plaque titration of plasma | IN, IT | 500,000 PFU | N/A | N/A |
| 19 | Yamayoshi et al.32       | Human calf | PCR (RT-qPCR): Nasal vestibule swab, nasopharyngeal, tracheal aspirate | N/A | 75–7500 PFU | N/A | Alveolar damage, involvement of the spleen, lymph nodes, different segments of the alimentary tract, kidney, adrenal gland, ovary, vesicular gland and prostate damage, gallbladder, myocardium, and lymph nodes. All the infected hamsters displayed severe systemic inflammatory responses |

TCID50: tissue culture infectious dose 50; PFU: plaque-forming unit; tgMice: transgenic mice; hACE2: human angiotensin converting enzyme 2; IN: intranasal; IG: intragastric; IO: intraocular; IT: intrathecal; IC: intracerebral; IP: intraperitoneal; CJ: conjunctivally; NR: not reported; DAA: Diasorin SARS-CoV-2 antigen detection assay; BAL: bronchoalveolar lavage.
body mass loss, and pneumonia were more severe in male
hamsters. All of Syrian golden hamsters infected via intra-
nasal route at a high dose of 10,000,000 PFU showed clinical
presentation.

The risk of bias assessment also demonstrated an accept-
able quality (score of 5 or more) for all the included studies
(Table 3).

Table 3. Newcastle–Ottawa scale (NOS) quality assessment of the study.

| First author         | Selection (out of 4) | Comparability (out of 2) | Exposure/outcome (out of 3) | Total (out of 9) |
|----------------------|----------------------|--------------------------|-----------------------------|-----------------|
| Bao et al.14         | ***                  | -                        | ***                         | 6               |
| Bao et al.15         | ***                  | -                        | ***                         | 6               |
| Basu16               | ****                 | *                        | ***                         | 8               |
| Bullard et al.17     | ****                 | *                        | ***                         | 8               |
| Bullard et al.18     | ****                 | *                        | ***                         | 7               |
| Chan et al.19        | ****                 | *                        | ***                         | 7               |
| Cross et al.20       | ***                  | -                        | **                          | 5               |
| Deng et al.21        | ****                 | -                        | ***                         | 7               |
| Dhakal et al.22      | ***                  | -                        | ***                         | 6               |
| Johnston et al.23    | ***                  | -                        | ***                         | 6               |
| Kumar et al.24       | ****                 | -                        | **                          | 6               |
| Rathnasinghe et al.25| ***                  | -                        | ***                         | 6               |
| Rosenke et al.26     | ***                  | -                        | ***                         | 6               |
| Ryan et al.27        | ****                 | -                        | ***                         | 6               |
| Sia et al.28         | ***                  | -                        | ***                         | 6               |
| Song et al.29        | ***                  | -                        | ***                         | 6               |
| Van der Moeren et al.30| ***              | *                        | **                          | 6               |
| Woolsey et al.31     | ***                  | -                        | ***                         | 6               |
| Yamayoshi et al.32   | ***                  | *                        | **                          | 6               |

Discussion

SARS-CoV-2, a lately found coronavirus accountable for
COVID-19, was first reported in China in late 2019 and then
extends rapidly worldwide. In this systematic review, we
have aimed to discover the average minimum infective dose
of SARS-CoV-2. The range of minimum infective was found
to be 1.26–7 \times 10^6 PFU. Many of the findings that illus-
trate the reaction of the immune system against the virus
have been experimented on animals such as mice, and the
studies on minimum infective dose yield consistent
results. It is vital to study the factors affecting transmis-
sibility and mortality of the COVID-19 to curb the current
pandemic, in order to predict the virus behavior in the host
body and inform the preventive measure to adjust accord-
ingly, it is essential that we find the average minimum infec-
tive dose of SARS-CoV-2. Although, the infective dose
differs significantly by virus and the way of administration,
for coronavirus mostly hundreds or even more virus particles
are needed to begin an infection. Due to the rapid spread of
the COVID-19 across the world, there are now more infected
cases. Many people have recovered from this viral infection;
however, more apprehension of virus biological behaviors is
needed to control the virus.

One of the factors that determine the spread of the virus
is its transmissibility. Finding the minimum infective dose
of the virus is one of the steps which bring us closer to
measuring the virus transmission power. To our knowledge,
minimum infective dose is required to start an infection,
because very low dosages of virus can be harmless. To sub-
stantiate this theory, the study by Bao et al. showed that
SARS-CoV-2 can be experimentally spread among hACE2
mice by close contact or through respiratory droplets, but it
is hardly transmitted through aerosol inoculation. This could
be justified by the amount of virus in the aerosol, which is
less than droplets, in some cases is not even enough to cause
infection; hence, a cut-off point for causing an infection
known as minimum infective dose for the virus is a very
useful indicator for virus infectivity in different exposure
occasions. According to Basu, based on a new computa-
tional strategy to quantify the infectious dose, it is estimated
that the particles needed to infect humans is possibly in the
order of hundreds.

A minimum infective dose indicates the amount of the
virus that causes infection and reflects on the probability of
infection. In line with this hypothesis, Ryan et al. show that
there is a relationship between the viral load and the severity
of the disease. These findings suggest that the low dose of
the virus could only cause mild infection, and even in five of
six ferrets did not cause infection. Another method that
indicated the number of virus titers is TCID50/mL, particu-
larly it measures the amount of virus needed to kill 50% of
tissue culture cells. Bullard et al. stated that the cycle thresh-
old value was highly prognostic of culture positivity. As
opposed to this statement, symptoms to test time were not
capable of discriminating between cases with positive and
negative cultures. This dose-response relationship between the mild and high viral dose group could reflect the relationship between minimum infective dose and disease severity.

Finding the minimum infective dose of the virus can be extremely useful in determining the transmission pattern. This represents itself in inconsistent results across the included studies; similar viral load did not cause the same outcome. This indicates that despite having a similar minimum infective dose, the infection rate could differ so this minimum is not the same across the same population. On the other hand, there are some human studies which have shown some hypothetical infective viral dosages. One of the most well discussed one is the study done by Basu et al., the main goal of which was to evaluate the size of the droplets which have high probability of causing infection. But besides this finding, they also had some points related to the viral load which can cause the infection. They found that the number of virions placing at a closely situated individual’s nasopharynx over the 2.5 h duration approximates to (11/5) virions per minute × 60 min × 2.5 h = 330. They also mentioned some related past studies done on ferrets (which showed 500 as the lower tested limit for the number of virions needed to launch an infection) and on humans but with SARS-CoV (the SARS-CoV dose that correlated to 10% and 50% adverse responses (i.e. illness) was estimated, respectively at 43 and 280 PU).16

This controversial point should be discussed in further studies, to find whether there can be a period of minimum infective dose or not, so the idea of minimum infective dose would be useful in determining the transmission of the disease.

This study has several limitations. First, we did not aim to conduct statistical analysis as the articles were limited, and the data and their ways of presentation were heterogeneous. Moreover, we had to include the pre-print studies (e.g. on bioRxiv) because of the limited number of studies and the existing evidence, and this problem could cause some studies that are not peer-reviewed and may have some errors in methodology and results, to leak into our data. Many of the studies were also laboratory or animal studies so the average minimum infective dose could vary from the actual human circumstances. Therefore, future studies are required to address the shortcomings of our study and to compensate for the lack of information regarding human models.

Conclusion
The results of this review suggest that one of the key factors to control the pandemic could be the study of virus transmission. The minimum infective dose is one of the main components of virus transmission. In this study, we have presented a range of minimum infective doses in humans and various animal species, yet such numbers can possibly vary between the individuals based on numerous factors. Measuring the minimum infective dose can provide a clearer overall understanding of the disease and its transmissibility and help better halt its spreading.

Acknowledgements
This study was conducted in collaboration with Khalkhal University of Medical Sciences, and Iranian Research Center for HIV/AIDS, Tehran University of Medical Sciences.

Author contributions
All the authors have read and approved the final version of the article. The conception and design of the study were performed by E.M. and S.S. Methodology was given by E.M., S.S., and A.K. Screening of the articles and acquisition of data were done by Z.P., P.M., N.J., H.M., S.D., F.A. Writing—original draft preparation was by A.B., A.F., S.K., A.K., and A.S. Writing—review & editing was by S.S. and O.D. Validation E.M., O.D., and S.S.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs
Nazanin Janfaza https://orcid.org/0000-0002-0990-620X
Esmaeil Mehraeen https://orcid.org/0000-0003-4108-2973
Omid Dadras https://orcid.org/0000-0001-9385-2170

Supplemental material
Supplemental material for this article is available online.

References
1. Zhao Q, Meng M, Kumar R, et al. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systemic review and meta-analysis. Int J Infect Dis 2020; 96: 131–135.
2. Oliaei S, SeyedAlinaghi S, Mehrtak M, et al. The effects of hyperbaric oxygen therapy (HBOT) on coronavirus disease-2019 (COVID-19): a systematic review. Eur J Med Res 2021; 26(1): 96.
3. SeyedAlinaghi S, Mehrtak M, MohsseniPour M, et al. Genetic susceptibility of COVID-19: a systematic review of current evidence. Eur J Med Res 2021; 26(1): 46.
4. Mehraeen E, Dadras O, Afshai AM, et al. Vaccines for COVID-19: a systematic review of feasibility and effectiveness. Infect Dis Drug Targ 2022; 22(2): e230921196758.
5. Sheikhbahaei E, Mirghaderi SP, Moharrami A, et al. Incidence of symptomatic COVID-19 in unvaccinated patients within one month after elective total joint arthroplasty: a multicenter study. Arthroplast Today 2022; 14: 110–115.
6. World Health Organization. WHO coronavirus (COVID-19) dashboard, 2021, https://covid19.who.int/
7. Park M, Cook AR, Lim JT, et al. A systematic review of COVID-19 epidemiology based on current evidence. J Clin Med 2020; 9(4): 967.

8. Gao Z, Xu Y, Sun C, et al. A systematic review of asymptomatic infections with COVID-19. J Microbiol Immunol Infect 2021; 54(1): 12–16.

9. Wu D, Wu T, Liu Q, et al. The SARS-CoV-2 outbreak: what we know. Int J Infect Dis 2020; 94: 44–48.

10. Liu K, Gu Z, Islam MS, et al. Global landscape of patents related to human coronaviruses. Int J Biol Sci 2021; 17(6): 1588–1599.

11. Abduljalil JM and Abduljalil BM. Epidemiology, genome, and clinical features of the pandemic SARS-CoV-2: a recent view. New Microbes New Infect 2020; 35: 100672.

12. Karimzadeh S, Bhopal R and Nguyen Tien H. Review of infections with COVID-19. J Microbiol Immunol Infect 2020; 54(1): 12–16.

13. Perera RA, Mok CK, Tsang OT, et al. Serological assays for SARS-CoV-2 infection: the clinical performance of a rapid lateral flow device. Emerg Microbes Infect 2020; 9(4): 967.

14. Bao L, Deng W, Huang B, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 2020; 583(7818): 830–833.

15. Bao L, Gao H, Deng W, et al. Transmission of severe acute respiratory syndrome coronavirus 2 via close contact and respiratory droplets among human angiotensin-converting enzyme 2 mice. J Infect Dis 2020; 222(4): 551–555.

16. Basu S. Computational characterization of inhaled droplet transport to the nasopharynx. Sci Rep 2021; 11(1): 1–13.

17. Bullard J, Dust K, Funk D, et al. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin Infect Dis 2020; 71(10): 2663–2666.

18. Bullard J, Funk D, Dust K, et al. Infectivity of severe acute respiratory syndrome coronavirus 2 in children compared with adults. CMAJ 2021; 193(17): E601–E606.

19. Chan JFW, Yip CCY, To KK, et al. Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens. J Clin Microbiol 2020; 58(5): e00310–e00320.

20. Cross RW, Agans KN, Prasad AN, et al. Intranasal exposure of African green monkeys to SARS-CoV-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase. Virol J 2020; 17(1): 1–12.

21. Deng W, Bao L, Gao H, et al. Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in rhesus macaques. Nat Commun 2020; 11(1): 1–7.

22. Dhakal S, Ruiz-Bedoya CA, Zhou R, et al. Sex differences in lung imaging and SARS-CoV-2 antibody responses in a COVID-19 golden Syrian hamster model, 2021. https://www.biorxiv.org/content/10.1101/2021.04.02.438292v1. full.pdf + html

23. Johnston SC, Ricks KM, Jay A, et al. Development of a coronavirus disease 2019 nonhuman primate model using airborne exposure. PLoS ONE 2021; 16(2): e0246366.

24. Kumar R, Kolloli A and Subbian S. Inactivation and elimination of SARS-CoV-2 in biosamples using simple fixatives and ultrafiltration. Meth Protoc 2021; 4(1): 18.

25. Rathnasinghe R, Strohmeier S, Amanat F, et al. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. Emerg Microbes Infect 2020; 9(1): 2433–2445.

26. Rosenke K, Meade-White K, Letko M, et al. Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection. Emerg Microbes Infect 2020; 9(1): 2673–2684.

27. Ryan KA, Bewley KR, Fotheringham SA, et al. Dose-dependent response to infection with SARS-CoV-2 in the ferret model: evidence of protection to re-challenge, 2020, https://www.biorxiv.org/content/10.1101/2020.05.29.123810v1

28. Sia SF, Yan LM, Chin AWH, et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 2020; 583(7818): 834–838.

29. Song Z, Bao L, Yu P, et al. SARS-CoV-2 causes a systemically multiple organs damages and dissemination in hamsters. Front Microbiol 2021; 11: 618891.

30. Van der Meer N, Zwart VF, Goderski G, et al. Performance of the Diasorin SARS-CoV-2 antigen detection assay on the LIAISON XL. J Clin Virol 2021; 141: 104909.

31. Woolsey C, Borisevich V, Prasad AN, et al. Establishment of an African green monkey model for COVID-19, 2020, https://pubmed.ncbi.nlm.nih.gov/32511377/

32. Yamayoshi S, Sakai-Tagawa Y, Koga M, et al. Comparison of rapid antigen tests for covid-19. Viruses 2020; 12(12): 1420.

33. Ward RL, Akin EW and D’Alessio DJ. Minimum infective dose of animal viruses. Crit Rev Environ Control 1984; 14(4): 297–310.

34. Carter J, Saunders V and Saunders VA. Virology: principles and applications. Hoboken, NJ: John Wiley & Sons, 2007.

35. SeyedAlinaghi S, Karimi A, MohsseniPour M, et al. The clinical outcomes of COVID-19 in HIV-positive patients: a systematic review of current evidence. Immun Inflamm Dis 2021; 9(4): 1160–1185.

36. SeyedAlinaghi S, Mirzapour P, Dadras O, et al. Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review. Eur J Med Res 2021; 26(1): 51.

37. Karimi A, Shobeiri P, Kulasinghe A, et al. Novel systemic inflammation markers to predict COVID-19 prognosis. Front Immunol 2021; 12: 741061.

38. Dadras O, Alinaghi SAS, Karimi A, et al. Effects of COVID-19 prevention procedures on other common infections: a systematic review. Eur J Med Res 2021; 26(1): 67.